According to Fortune Business Insights, the global bioanalytical testing services market size was valued at USD 5.72 billion in 2025 and is projected to grow from USD 6.26 billion in 2026 to USD 12.30 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 8.8% during the forecast period. The market is experiencing significant growth due to the expansion of pharmaceutical and biotechnology research and development (R&D), increasing demand for biologics and advanced therapeutic modalities, and the rising outsourcing of analytical testing activities. Furthermore, growing interest in precision medicine and biomarker-based research is increasing the need for reliable bioanalytical services across preclinical studies and clinical trials. North America dominated the global market, accounting for a 43.53% share in 2025.
Bioanalytical Testing Services Market Overview
Bioanalytical testing services involve the identification and quantification of drugs, metabolites, and other biological substances in biological samples, including blood, plasma, urine, and tissues. These services are essential for evaluating drug absorption, distribution, metabolism, and excretion, as well as assessing drug safety, efficacy, and therapeutic responses throughout the drug development process.
Pharmaceutical and biotechnology companies rely on bioanalytical testing to generate accurate data for preclinical research, clinical trials, regulatory submissions, and the development of new treatments. Specialized laboratories and contract research organizations (CROs) provide analytical capabilities that help drug developers improve testing efficiency and meet regulatory requirements.
The growing development of monoclonal antibodies, biosimilars, cell and gene therapies, and other complex treatments is increasing demand for advanced analytical methods. At the same time, pharmaceutical companies are increasingly outsourcing testing activities to specialized service providers to access technical expertise, advanced laboratory infrastructure, and scalable testing capabilities.
Key Bioanalytical Testing Services Market Trends
Digitalization and Automation of Laboratory Workflows
Digitalization and automation are emerging as important trends in the bioanalytical testing services market. Laboratories are increasingly adopting automated liquid-handling systems, robotic sample preparation, laboratory information management systems, and connected analytical instruments to improve operational efficiency.
Automation helps minimize manual errors, improve consistency, and accelerate the processing of large sample volumes. Digital platforms also enable sample tracking, centralized data management, and improved traceability throughout testing workflows. These capabilities are particularly valuable for laboratories managing complex clinical trials and large-scale drug development programs.
Growing Demand for Biologics and Advanced Therapeutics
The increasing development of biologics and advanced therapeutic modalities is creating demand for specialized bioanalytical testing services. Monoclonal antibodies, biosimilars, cell therapies, gene therapies, and other complex treatments require sophisticated analytical methods to assess drug concentration, immunogenicity, biomarkers, and therapeutic responses.
As pharmaceutical companies expand their biologics pipelines, testing providers are investing in advanced analytical technologies and specialized laboratory capabilities. This trend is expected to support market expansion throughout the forecast period.
Increasing Outsourcing of Bioanalytical Testing
Pharmaceutical and biotechnology companies are increasingly outsourcing bioanalytical testing to CROs and specialized laboratories. Outsourcing allows drug developers to reduce the need for significant capital investments in laboratory infrastructure, access experienced scientific teams, and manage changing testing requirements throughout the development lifecycle.
Specialized service providers also offer expertise in assay development, method validation, pharmacokinetic analysis, immunogenicity testing, and regulatory-compliant data management. The growing complexity of drug development is expected to strengthen demand for outsourced bioanalytical services.
Request a Free Sample: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bioanalytical-testing-services-market-111607
Bioanalytical Testing Services Market Growth Drivers
Expansion of Pharmaceutical and Biotechnology R&D
The expansion of pharmaceutical and biotechnology R&D pipelines is a major driver of market growth. Drug developers are investing in research targeting oncology, neurological disorders, metabolic diseases, rare diseases, and other therapeutic areas. Each development program may require extensive testing to evaluate drug concentrations, biological responses, safety, and efficacy.
As the number of preclinical studies and clinical trials increases, demand for reliable bioanalytical testing services is expected to rise. These services help researchers generate the scientific evidence required to advance drug candidates through development and regulatory review.
Rising Adoption of Precision Medicine
Precision medicine focuses on developing treatments based on individual patient characteristics, molecular profiles, and biological markers. Bioanalytical testing supports this approach by enabling researchers to measure biomarkers, evaluate treatment responses, and understand the relationship between drug exposure and therapeutic outcomes.
The increasing use of biomarker-driven clinical trials and targeted therapies is creating opportunities for providers with advanced analytical capabilities. Demand for sensitive and reliable testing methods is expected to increase as personalized treatment approaches become more widely adopted.
Stringent Regulatory Requirements for Drug Development
Regulatory authorities require pharmaceutical companies to demonstrate the quality, safety, and efficacy of drug candidates through reliable analytical data. Bioanalytical laboratories play a critical role in meeting these requirements by conducting validated assays, maintaining data integrity, and following appropriate quality standards.
The need for consistent and reproducible results is encouraging pharmaceutical companies to work with specialized testing providers that have the required technical expertise and quality systems.
Bioanalytical Testing Services Market Segmentation Analysis
The market is segmented by analytical testing type, molecule, technology, end user, and region.
By Analytical Testing Type
The pharmacokinetic/toxicokinetic and drug concentration analysis segment held the largest market share in 2025. These services help researchers understand drug absorption, distribution, metabolism, and elimination, making them essential throughout preclinical and clinical drug development.
Other key segments include immunogenicity testing, biomarker and pharmacodynamic analysis, and metabolite profiling and identification. Immunogenicity testing is expected to grow as demand increases for biologics and advanced therapies that require detailed assessments of immune responses.
By Molecule
The market is categorized into small molecules, large molecules and conventional biologics, and advanced therapeutic modalities.
The large molecules and conventional biologics segment dominated the market in 2025, accounting for 39.9% of the total market. The segment benefits from the growing development of monoclonal antibodies, biosimilars, and other biologic treatments, which require specialized analytical testing.
Advanced therapeutic modalities are also expected to experience strong growth as pharmaceutical companies expand research into cell therapies, gene therapies, and other innovative treatment approaches.
By Technology
The market includes direct chromatography–mass spectrometry, ligand-binding and immunoassays, flow cytometry, and other technologies.
Direct chromatography–mass spectrometry held the largest share in 2025, accounting for 37.8% of the market. Its high sensitivity, selectivity, and ability to quantify compounds in complex biological samples make it valuable for pharmaceutical research.
Flow cytometry is expected to register substantial growth as its applications expand in cellular analysis, immunology, and advanced therapeutic development.
By End User
Pharmaceutical and biotechnology companies represented the leading end-user segment in 2025. These organizations require bioanalytical services to support drug discovery, clinical development, pharmacokinetic studies, and regulatory submissions.
Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are also important users of these services. Their growing role in outsourced drug development is expected to support demand for specialized testing capabilities.
Academic institutions and research organizations contribute to the market by conducting experimental research, biomarker investigations, and early-stage drug development.
Bioanalytical Testing Services Market Regional Outlook
North America
North America dominated the global bioanalytical testing services market in 2025, accounting for 43.53% of total revenue, equivalent to approximately USD 2.49 billion. The region benefits from a strong pharmaceutical and biotechnology industry, substantial clinical research activity, advanced laboratory infrastructure, and the presence of major service providers.
The U.S. represents a significant contributor to regional demand because of its extensive drug development ecosystem and established network of clinical research organizations. Continued investment in biologics, precision medicine, and specialized laboratory services is expected to support regional growth.
Europe
Europe is expected to remain a major market during the forecast period. The region benefits from established pharmaceutical manufacturing, biotechnology research, and regulatory frameworks supporting drug development.
Increasing adoption of liquid chromatography–tandem mass spectrometry (LC-MS/MS), rising investments in clinical research, and the development of biologics are expected to contribute to market expansion. Germany and the U.K. remain important national markets within the region.
Asia Pacific
Asia Pacific is expected to witness growing demand for bioanalytical testing services due to expanding pharmaceutical manufacturing, increasing clinical trial activity, and improvements in laboratory infrastructure.
China, India, and Japan are important markets in the region. Growing healthcare expenditure, the expansion of biotechnology research, and increasing participation in global drug development programs are creating opportunities for service providers.
Latin America and the Middle East & Africa
Latin America is expected to experience market growth as clinical research activity expands and pharmaceutical companies seek additional testing capabilities. Brazil and Mexico represent important opportunities for providers looking to strengthen their presence in emerging markets.
The Middle East and Africa region is also expected to develop gradually as healthcare infrastructure, research institutions, and specialized laboratory capabilities expand. However, limited research infrastructure and the relatively small presence of research-intensive pharmaceutical companies in some countries may constrain adoption.
Competitive Landscape of the Bioanalytical Testing Services Market
The competitive landscape includes established laboratory service providers, contract research organizations, and specialized analytical testing companies. Market participants are focusing on laboratory expansion, acquisitions, technology upgrades, and broader service portfolios to strengthen their competitive positions.
Key companies operating in the global bioanalytical testing services market include:
- Thermo Fisher Scientific Inc.
- SGS Société Générale de Surveillance SA
- Labcorp
- IQVIA
- Charles River Laboratories
- Eurofins Scientific
- Intertek Group plc
- WuXi AppTec
- Pharmaron
- Frontage Labs
Companies are increasingly investing in advanced mass spectrometry platforms, biomarker analysis, immunogenicity testing, and automated laboratory workflows. Strategic acquisitions are also enabling providers to expand geographic reach and specialized testing capabilities.
For example, SGS announced acquisitions of CMIC, Inc. in June 2026 and Keystone Bioanalytical in May 2026 to strengthen its bioanalytical testing presence in North America. Such activities reflect the industry's focus on expanding technical expertise and service capacity.
Read Report Insights: https://www.fortunebusinessinsights.com/bioanalytical-testing-services-market-111607
Future Outlook
The global bioanalytical testing services market is expected to experience sustained growth through 2034 as pharmaceutical R&D pipelines expand and advanced therapies become more prominent. Increasing outsourcing, growing demand for precision medicine, and the adoption of automated analytical technologies are expected to create opportunities for established providers and emerging service companies.
However, high equipment costs, shortages of skilled scientists, and the complexity of assay development and regulatory compliance may constrain market expansion. Companies that combine scientific expertise, advanced analytical platforms, reliable data management, and scalable laboratory operations are likely to be well positioned to benefit from growing demand.
5 Trending FAQs on the Bioanalytical Testing Services Market
- What is the global bioanalytical testing services market size?
According to Fortune Business Insights, the global bioanalytical testing services market was valued at USD 5.72 billion in 2025 and is projected to reach USD 12.30 billion by 2034.
- What is the expected CAGR of the bioanalytical testing services market?
The market is expected to grow at a CAGR of 8.8% during the forecast period from 2026 to 2034.
- Which segment dominates the bioanalytical testing services market?
By analytical testing type, pharmacokinetic/toxicokinetic and drug concentration analysis held the leading position in 2025. By molecule, large molecules and conventional biologics dominated with a 39.9% market share, while direct chromatography–mass spectrometry led the technology segment with a 37.8% share.
- Who are the key players in the bioanalytical testing services market?
Major companies include Thermo Fisher Scientific Inc., SGS Société Générale de Surveillance SA, Labcorp, IQVIA, Charles River Laboratories, and Eurofins Scientific. Other participants include Intertek Group plc, WuXi AppTec, Pharmaron, and Frontage Labs.
- What are the major trends driving the bioanalytical testing services market?
Key trends include laboratory automation and digitalization, increasing outsourcing of analytical testing, growing demand for biologics and advanced therapies, expansion of pharmaceutical R&D pipelines, and rising adoption of precision medicine and biomarker-based research. These developments are increasing demand for accurate, efficient, and specialized bioanalytical testing services.
Curious About Japan’s Market? Explore the Latest - bioanalytical testing services market- Insights